Friday Mar 7
The Motley Fool
The Spark of Innovation at Vertex Pharmaceuticals Incorporated
There's little room for error in the biotech industry. The discovery and development of new drugs is a long, arduous process that sometimes takes a decade to complete, and precision is necessary at every step.
Trending on the Topix Network
Friday Mar 7
Vertex Pharmaceuticals Receives Consensus Rating of "Buy" from Analysts
Shares of Vertex Pharmaceuticals have been given an average recommendation of "Buy" by the twenty-one analysts that are covering the stock, Analyst Ratings.Net reports .
Friday Mar 7
Stocks up on strong February jobs report
Once you're logged in, at the top of each article, video or slideshow you will see a list of your Facebook friends who recently visited Choose to share stories you'e read with your friends or turn sharing OFF to keep your reading experience anonymous .
Thu Mar 06, 2014
Customer Interaction Solutions
Vertex to Present at the Barclays Global Healthcare Conference on March 11
Vertex Pharmaceuticals Incorporated today announced that it will present at the Barclays Global Healthcare Conference on Tuesday, March 11 at 8:00 a.m. ET.
Fri Feb 28, 2014
From Startup To Billion-Dollar Biotech: An Inside Look At Vertex Pharmaceuticals
Vertex Pharmaceuticals is a rare biotech success story. Started in 1989 by chemist Joshua Boger, the company was fueled for many years by three key ingredients: a unique approach to drug discovery, the tenacious dedication of a small group of scientists, and an ambitious long-term vision.
Mon Feb 24, 2014
FDA Approves Kalydeco (Ivacaftor) for Use in Eight Additional Mutations That Cause Cystic Fibrosis
The FDA has approved a supplemental new drug application for Kalydeco for people aged 6 years and older with cystic fibrosis who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator gene.
Vertex Pharmaceuticals Price Target Increased to $92.00 by Analysts at Maxim Group
The firm currently has a "buy" rating on the stock. Maxim Group's price objective indicates a potential upside of 8.48% from the company's current price.
Fri Feb 21, 2014
U.S. Food and Drug Administration Approves KALYDECOa (ivacaftor)...
Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved a supplemental New Drug Application for KALYDECOTM for people with cystic fibrosis ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator gene.
Thu Feb 20, 2014
Vertex to Present at the RBC Global Healthcare Conference on February 25
Vertex Pharmaceuticals Incorporated today announced that it will be presenting at the 2014 RBC Capital Markets Global Healthcare Conference on Tuesday, February 25 at 1:35 p.m. ET.
Stuart Schreiber on how H3 Biomedicine is poised for 'radical change'
Stuart L. Schreiber, director of the Center for the Science of Therapeutics at the Broad Institute of Harvard and MIT.
Solarbuzz: Solar projects up to 5MW drive 95GW project pipeline, Digitimes says
Stocks with call strike movement; VRTX FSLR Vertex May 92.5 call option implied volatility increased 6% to 61, First Solar June 62.5 call option implied volatility increased 4% to 61 according to IVolatility.
Fri Feb 14, 2014
Vertex Pharmaceuticals Upgraded to "Hold" by TheStreet
The analysts wrote, "Vertex Pharmaceuticals has been upgraded by TheStreet Ratings from sell to hold.
Thu Feb 13, 2014
The pharmaceutical industry: When the times were a-changing
Wed Feb 12, 2014
BorgWarner appoints Vicki L. Sato to Board of Directors
BorgWarner announced today that Vicki L. Sato has been named to its board of directors.
Newton Trust Spends $1.1 Billion for Two Seaport District Towers
Senior Housing Properties Trust of Newton will pay $1.1 billion for two Seaport District towers, which will house Vertex Pharmaceuticals Inc. headquarters.
Tue Feb 11, 2014
Drug Discovery - Even When You Win, You Still Can Lose
Director of chemical and pharmaceutical sciences at The American Council on Science and Health in New York since 2010.
Insider Selling: Jeffrey M. Leiden Unloads 35,944 Shares of Vertex Pharmaceuticals Stock
Vertex Pharmaceuticals CEO Jeffrey M. Leiden unloaded 35,944 shares of the company's stock on the open market in a transaction dated Friday, February 7th.
Senior Housing Properties' Management Presents at Acquisition of Two...
Senior Housing Properties Trust Acquisition of Two Biotech Medical Office Buildings in Boston's Seaport District Conference Call February 11, 2014 10:00 AM ET Good day and welcome to the Senior Housing Properties Trust Conference Call.
The search for the magic bullet
Fortune.com selects the most compelling short essays, anecdotes, and author interviews from " 250 Words ," a site developed by Simon & Schuster to explore the best new business books -- wherever they may be published.